Was doing a little calculating. As of late May/June 2015, right before the 1 for 150 R/S, AMBS had over 1 billion shares outstanding (1,059,000,000 to be exact) and was trading at 5.1 cents. That gave it a MC of 54 million. Today the market cap is nowhere near that. Even if we had 200,000,000 shares out right now (68M listed, but obviously it's higher), MC would still only be 13 million. In addition, not a single asset in the pipe has had a data setback that would justify a reduced market cap. If anything, the MC should be increasing now that we are acquiring some SeD Biomedical assets and further along in Elto and ESS. Also, MANF's complimentary protein growth factor, CDNF, is entering human trials this year in Europe. No reason MANF shouldn't be able to as well as we push forward.

Still a ton of room to run as things begin to transpire, and now AMBS has a serious foothold in China.